{"id":604634,"date":"2022-06-20T19:08:01","date_gmt":"2022-06-20T19:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=604634"},"modified":"2022-06-20T19:08:01","modified_gmt":"2022-06-20T19:08:01","slug":"sarcopenia-market-to-register-incremental-growth-during-the-forecast-period-2032-asserts-delveinsight-key-companies-eli-lily-sanofi-biophytis-novartis-amazentis-immunoforge-and-regeneron","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sarcopenia-market-to-register-incremental-growth-during-the-forecast-period-2032-asserts-delveinsight-key-companies-eli-lily-sanofi-biophytis-novartis-amazentis-immunoforge-and-regeneron_604634.html","title":{"rendered":"Sarcopenia Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies – Eli Lily, Sanofi, Biophytis, Novartis, Amazentis, Immunoforge, and Regeneron"},"content":{"rendered":"
\n
\"Sarcopenia<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sarcopenia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Sarcopenia market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Sarcopenia<\/p>\n

Sarcopenia: An Overview<\/strong><\/p>\n

Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.<\/p>\n

Trials with various agents, including selective androgen receptor modulators and myostatin inhibitors, show promise as future treatment options. To date, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. To achieve that, increased awareness of sarcopenia is of great importance to begin reaching a consensus on diagnosis and to contribute to finding a cure for this condition.<\/em><\/p>\n

Sarcopenia Market Key Facts<\/strong><\/p>\n